alexa A Novel Anti-diabetes Drug Development Program | OMICS International
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Diabetes & Metabolism
November 03-05, 2014 Embassy Suites Las Vegas, USA

Moon K Song
ScientificTracks Abstracts: J Diabetes Metab
DOI: 10.4172/2155-6156.S1.026
Over the last 50 years, the most extensively used blood glucose controlling agents have been insulin and sulfonylurea derivatives. However, more recently developed anti-diabetes drugs exhibit moderate to serious side effects. Rosiglitazone and pioglitazone are the only anti-diabetes drugs that improve insulin resistance, the primary cause of type 2 diabetes. Nevertheless, they have severe side effects: liver damage. We have demonstrated that Cyclo (his-pro) plus zinc (Cyclo-Z) is very effective in lowering blood glucose levels and improving oral glucose tolerance in streptozocin-induced diabetic rats, genetic type 2 diabetic Goto-Kakizaki (G-K) rats, and genetically obese diabetic ob/ob mice. Furthermore, Cyclo-Z treatment reduced body weight in obese Sprague-Dawley rats and aged G-K rats by reducing food and water intake. In these studies and along with subsequent nine-month toxicological studies in rats, we have not observed any adverse effects of Cyclo-Z. In an FDA-IND approved Phase 1 clinical trial, acute (24 hr study) high doses of Cyclo-Z also did not demonstrate any adverse effects in human volunteers. Findings from a three month Phase 2a clinical trial showed significant reductions in body weight and HbA1c in mildly diabetic, obese patients without a single report of any side effects. A second Phase 2a clinical trial is currently underway with severely diabetic, obese subjects. Given that Cyclo-Z does not show any apparent untoward effects and yet it improves insulin resistance in both animals and humans, Cyclo-Z may potentially be the most significant FDA approved new drug for the treatment of both diabetes and obesity.
Moon K Song has completed his PhD from the University of Hawaii and Postdoctoral studies at the Indiana University School of Medicine. He currently is the Principal Investigator studying Metabolic Disease Research at the VA Greater Los Angeles Healthcare System and is an Emeritus Research Professor at the UCLA School of Medicine. He has published >75 papers in reputable journals, and has presented his findings at numerous professional and scientific conferences (>70 times). He has reviewed manuscripts for >20 biomedical scientific journals and grant proposals from more than five different funding agencies and currently maintains five professional society memberships.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version